CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Intermediate dose thromboprophylaxisWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug579 Clevudine Wiki 1.00
drug2325 Standard of Care thromboprophylaxis Wiki 1.00
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D020141 Hemostatic Disorders NIH 0.30
D001778 Blood Coagulation Disorders NIH 0.30

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0001928 Abnormality of coagulation HPO 0.30

There is one clinical trial.

Clinical Trials


1 COVID-19-associated Coagulopathy: Safety and Efficacy of Prophylactic Anticoagulation Therapy in Hospitalized Adults With COVID-19

This prospective, randomized, open-label, multi-center interventional study is designed to compare the safety and efficacy of two LMWH dosing protocols in patients admitted to the University of Iowa Hospitals with COVID-19 who meet the modified ISTH Overt DIC criteria score ≥3. Patients will be randomized to standard prophylactic dose LMWH (standard of care arm) or intermediate-dose LMWH (intervention arm).

NCT04360824 COVID 19 Associated Coagulopathy Drug: Intermediate dose thromboprophylaxis Drug: Standard of Care thromboprophylaxis
MeSH:Hemostatic Disorders Blood Coagulation Disorders
HPO:Abnormality of coagulation Abnormality of the coagulation cascade

Primary Outcomes

Description: Risk of all-cause mortality

Measure: Mortality

Time: 30 Days post intervention

Secondary Outcomes

Description: Risk of ISTH defined major bleeding

Measure: Major Bleeding

Time: 30 Days post intervention

Description: Risk of ischemic stroke, myocardial infarction and/or limb ischemia

Measure: Arterial Thrombosis

Time: 30 Days post intervention

Description: Risk of symptomatic venous thromboembolism

Measure: Venous Thromboembolism

Time: 30 Days post intervention

Description: duration of intensive care measures

Measure: ICU admission, intubation/ventilation

Time: 30 Days post intervention

Description: The number of units of packed red blood cells transfused

Measure: Packed Red Blood Cell Transfusions

Time: 30 Days post intervention

Description: The number of units of platelets transfused

Measure: Platelet Transfusions

Time: 30 Days post intervention

Description: The number of units of Fresh Frozen Plasma Transfused

Measure: Fresh Frozen Plasma Transfusions

Time: 30 Days post intervention

Description: The number of units of Cryoprecipitate Transfused

Measure: Cryoprecipitate Transfusions

Time: 30 Days post intervention

Description: The number of units of Prothrombin Complex ConcentrateTransfused

Measure: Prothrombin Complex Concentrate Transfusions

Time: 30 Days post intervention

Other Outcomes

Description: Will be performed in stored plasma using Calibrated Automated Thrombogram. The endogenous thrombin potential will be calculated in units of nM.Min.

Measure: The endogenous thrombin potential will be determined within 24 hours of randomization and weekly for 30 days or until hospital discharge

Time: 30 days post intervention

Description: These assays will be performed in stored plasma. Quantification of cfDNA will be performed using Qubit dsDNA HS Assay kit. Histones H4, citrullinated-histone and DNA-myeloperoxidase will be measured using commercially available ELISA kit.

Measure: Plasma levels of cell-free DNA will be determined within 24 hours of randomization and weekly for 30 days or until hospital discharge

Time: 30 days post intervention

Description: will be measured in stored plasma using a commercially available ELISA kit.

Measure: PAI-1

Time: 30 days post intervention


Related HPO nodes (Using clinical trials)